Effect of coadministration of angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) on variability of home blood pressure in hypertensive outpatients
Not Applicable
- Conditions
- Hypertension
- Registration Number
- JPRN-UMIN000010213
- Lead Sponsor
- Department of Nephrology and Hypertension, Kawasaki Medical School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with the past history of hypersensitivity to test drugs, other ARBs or dihydropyridine CCBs 2) Female in current or expected pregnancy 3) Patients with the past history of cerebro-cardiovascular diseases within six months 4) Patients whose blood pressures show more than 180/110mmHg 5) Patients receiving the dialysis therapy or with severe renal dysfunction (eGFR<30ml/min/1.73m2) 6) Patients with severe hepatic dysfunction (showing more than 100 IU/L of AST or ALT) 7) Patients receiving treatment for a malignant neoplasm 8) Patients taking a contraindication drug for coadministration of test drugs 9) Patients judged as unsuitable for participating in this study by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of home blood pressure variability
- Secondary Outcome Measures
Name Time Method 1) Change of blood pressure at clinic and home 2) Change of pulse rate at clinic and home 3) Change of cardiac function (double product: pulse rate x systolic blood pressure) 4) Change of renal function (eGFR: estimated glomerular filtration rate) 5) Change of albuminuria 6) Incidence and degree of detrimental events